Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Anbogen Therapeutics, Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07244705CT.gov A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC | — | Recruiting | — | — | — |
NCT06856837CT.gov - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases | — | Recruiting | — | — | — |
NCT07136077CT.gov A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy | — | Recruiting | — | — | — |
NCT06332274CT.gov tislelizUMaB in canceR Patients With molEcuLar residuaL Disease | — | Recruiting | — | — | — |
NCT06848465CT.gov LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis | — | Recruiting | — | — | — |
NCT06585488CT.gov A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | — | Terminated | — | — | — |
NCT06520683CT.gov Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer | — | Recruiting | — | — | — |
NCT06529523CT.gov Tislelizumab in People With Colorectal Cancer | — | Recruiting | — | — | — |
NCT06504901CT.gov Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases | — | Not Yet Recruiting | — | — | — |
NCT06218888CT.gov A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases | — | Not Yet Recruiting | — | — | — |
Show 22 more trialsShow fewer
NCT06881537CT.gov CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer | — | Recruiting | — | — | — |
NCT05841134CT.gov Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT05789069CT.gov A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05799443CT.gov Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer | — | Unknown | — | — | — |
NCT05771181CT.gov Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | — | Recruiting | — | — | — |
NCT05651022CT.gov Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05609370CT.gov A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05435313CT.gov Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | — | Unknown | — | — | — |
NCT05350917CT.gov Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy | — | Not Yet Recruiting | — | — | — |
NCT05314101CT.gov TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer | — | Unknown | — | — | — |
NCT05116085CT.gov Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer | — | Completed | — | — | — |
NCT05167071CT.gov HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study | — | Active Not Recruiting | — | — | — |
NCT04952753CT.gov Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC | — | Terminated | — | — | — |
NCT04948034CT.gov The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) | — | Unknown | — | — | — |
NCT04577963CT.gov A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04802876CT.gov Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors | — | Active Not Recruiting | — | — | — |
NCT04777162CT.gov Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer | — | Unknown | — | — | — |
NCT04666688CT.gov LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT04294160CT.gov A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer | — | Terminated | — | — | — |
NCT04227041CT.gov A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer | — | Unknown | — | — | — |
NCT04380012CT.gov A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT03843749CT.gov Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar. | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pyrotinib (this asset) | Anbogen Therapeutics, Inc. | P3 | B · 61 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Pyrotinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BB · 70 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 66 |
| Invasive Breast Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pyrotinib in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pyrotinib-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →